Advertisement

Neurocritical Care

, 9:366 | Cite as

High-dose Dexmedetomidine-induced Hypertension in a Child with Traumatic Brain Injury

  • Gwen Erkonen
  • Fred Lamb
  • Joseph D. TobiasEmail author
Practical Pearl

Abstract

Introduction

Dexmedetomidine is a centrally acting α2-adrenergic agonist which is currently FDA-approved for the short-term (less than 24 h) sedation of adults during mechanical ventilation.

Discussion

Given its beneficial physiologic properties, there has been increasing use of this agent in the pediatric population. As with any agent used for sedation in the Pediatric ICU setting, dose escalations may be necessary. Unlike benzodiazepines and opioids, there are limited data regarding the administration of dexmedetomidine above the current package insert dosing recommendations of 0.7 μg/kg/h.

Results

We report a 2-year-old child with traumatic brain injury who developed hypertension following the administration of a dexmedetomidine infusion at 4 μg/kg/h for several hours. Investigation into the etiology of the hypertension was negative and the blood pressure returned to baseline with a decrease in the infusion rate.

Conclusion

Subsequent to this, no further issues with hypertension were noted.

Keywords

Dexmedetomidine Hypertension Traumatic brain injury 

References

  1. 1.
    Virtanen R, Savola JM, Saano V, Nyman L. Characterization of selectivity, specificity, and potency of medetomidine as an alpha2-adrenoceptor agonist. Eur J Pharmacol. 1998;150:9–14.CrossRefGoogle Scholar
  2. 2.
    Tobias JD. Dexmedetomidine: applications in pediatric critical care and pediatric anesthesiology. Pediatr Crit Care Med. 2007;8:115–31.PubMedCrossRefGoogle Scholar
  3. 3.
    Bloor BC, Ward DS, Belleville JP, et al. Effects of intravenous dexmedetomidine in humans, II: hemodynamic changes. Anesthesiology. 1992;77:1134–42.PubMedCrossRefGoogle Scholar
  4. 4.
    Venn RM, Bradshaw CJ, Spencer R, et al. Preliminary UK experience of dexmedetomidine, a novel agent for postoperative sedation in the intensive care unit. Anaesthesia. 1999;54:1136–42.PubMedCrossRefGoogle Scholar
  5. 5.
    Talke P, Tong C, Lee HW, et al. Effect of dexmedetomidine on lumbar cerebrospinal fluid pressure in humans. Anesth Analg. 1997;85:358–64.PubMedCrossRefGoogle Scholar
  6. 6.
    Zornow MH, Scheller MS, Sheehan PB, Strant MAP, Matsumoto M. Intracranial pressure effects of dexmedetomidine in rabbits. Anesth Analg. 1992;75:232–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Karlsson BR, Forsman M, Roald OK, et al. Effect of dexmedetomidine, a selective and potent α2-agonist, on cerebral blood flow and oxygen consumption during halothane anesthesia in dogs. Anesth Analg. 1990;71:125–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Prielipp RC, Wall MH, Tobin JR, et al. Dexmedetomidine-induced sedation in volunteers decreases regional and global cerebral blood flow. Anesth Analg. 2002;95:1052–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Aryan HE, Box KW, Irahim D, et al. Safety and efficacy of dexmedetomidine in neurosurgical patients. Brain Inj. 2006;20:791–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Tobias JD, Berkenbosch JW. Sedation during mechanical ventilation in infants and children: dexmedetomidine versus midazolam. South Med J. 2004;97:451–5.PubMedCrossRefGoogle Scholar
  11. 11.
    Drummond JC, Dao AV, Roth DM, et al. Effect of dexmedetomidine on cerebral blood flow velocity, cerebral metabolic rate, and carbon dioxide response in normal humans. Anesthesiology. 2008;108:225–32.PubMedGoogle Scholar
  12. 12.
    Guidelines for the acute medical management of severe traumatic brain injury in infants, children, and adolescents. Use of sedation and neuromuscular blockade in the treatment of severe pediatric traumatic brain injury (chapter 9). Pediatr Crit Care Med. 2003;4:S34–7.Google Scholar
  13. 13.
    Spitzfaden AC, Jimenez DF, Tobias JD. Propofol for sedation and control of intracranial pressure in children. Pediatr Neurosurg. 1999;31:194–200.PubMedCrossRefGoogle Scholar
  14. 14.
    Wheeler A, Bothwell M, Tobias JD. Prevention of medication withdrawal following laryngotracheoplasty. Am J Pain Manage. 2005;15:15–21.Google Scholar
  15. 15.
    Hammer GB, Philip BM, Schroeder AR, et al. Prolonged infusion of dexmedetomidine for sedation following tracheal resection. Pediatr Anesth. 2005;15:616–20.CrossRefGoogle Scholar
  16. 16.
    Chrysostomou C, Zeballos T. Use of dexmedetomidine in a pediatric heart transplant patient. Pediatr Cardiol. 2005;26:651–4.PubMedCrossRefGoogle Scholar
  17. 17.
    Chrysostomou C, Di Filippo S, Manrique AM, et al. Use of dexmedetomidine in children after cardiac and thoracic surgery. Pediatr Crit Care Med. 2006;7:126–31.PubMedCrossRefGoogle Scholar
  18. 18.
    Walker J, Maccallum M, Fischer C, et al. Sedation using dexmedetomidine in pediatric burn patients. J Burn Care Res. 2006;27:206–10.PubMedGoogle Scholar
  19. 19.
    Mason KP, Zgleszewski SE, Dearden JL, et al. Dexmedetomidine for pediatric sedation for computed tomography imaging studies. Anesth Analg. 2006;103:57–62.PubMedCrossRefGoogle Scholar
  20. 20.
    Mason KP, Zurakowski D, Zgleszewski SE, et al. High dose dexmedetomidine as the sole sedative for pediatric MRI. Pediatr Anesth. 2008;18:403–11.CrossRefGoogle Scholar
  21. 21.
    Mason KP, Zgleszewski SE, Prescilla R, et al. Hemodynamic effects of dexmedetomidine sedation for CT imaging studies. Pediatr Anesth. 2008;18:393–402.CrossRefGoogle Scholar
  22. 22.
    Hammer GB, Drover DR, Cao H, et al. The effects of dexmedetomidine on cardiac electrophysiology in children. Anesth Analg. 2008;106:79–83.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2008

Authors and Affiliations

  1. 1.Department of PediatricsUniversity of IowaIowa CityUSA
  2. 2.Department of AnesthesiologyUniversity of MissouriColumbiaUSA
  3. 3.Department of PediatricsUniversity of MissouriColumbiaUSA

Personalised recommendations